[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-336250-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-336250-en":131},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","prognostic-value-of-hhla2-in-patients-with-solid-tumors-a-meta-analysis","Prognostic Value of HHLA2 in Patients with Solid Tumors - A Meta-Analysis","","HHLA2 is a B7-family immune checkpoint with context-dependent co-stimulatory or co-inhibitory effects in cancer. This meta-analysis evaluated whether HHLA2 expression levels are associated with prognosis in patients with solid tumors. Data were collected from PubMed, Embase, Web of Science, Cochrane, and Scopus and analyzed using R. Eighteen studies covering 2,880 patients were pooled to assess OS, DSS, PFS, RFS, and DFS, showing that high HHLA2 expression correlated with poorer clinical outcomes.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/prognostic-value-of-hhla2-in-patients-with-solid-tumors-a-meta-analysis/336250/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/prognostic-value-of-hhla2-in-patients-with-solid-tumors-a-meta-analysis/336250.png","ImageObject",300,407,{"name":42,"@type":43},"Aurora","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-27","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",14,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is HHLA2 and why is it relevant to cancer prognosis?","Question",{"text":63,"@type":64},"HHLA2 is an immune checkpoint from the B7 family that can act as co-stimulatory or co-inhibitory depending on its receptor interactions. Because it influences anti-tumor immune activity, it may impact patient outcomes.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How was the meta-analysis conducted and which databases were used?",{"text":68,"@type":64},"The study pooled data from PubMed, Embase, Web of Science, Cochrane, and Scopus. R studio software was used for statistical analysis with hazard ratio pooling across survival endpoints.",{"name":70,"@type":61,"acceptedAnswer":71},"What outcomes were associated with high HHLA2 expression in solid tumors?",{"text":72,"@type":64},"High HHLA2 expression was linked to worse overall survival (OS), shorter recurrence-free survival (RFS), and worse disease-free survival (DFS) across the included studies.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},336250,1790499258,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,127],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":124,"doc_module":4,"doc_module_name":25,"category_name":125,"show_sort_weight":124,"slug":126},10,"Lifestyle","lifestyle",{"id":128,"doc_module":4,"doc_module_name":25,"category_name":129,"show_sort_weight":97,"slug":130},19,"General","general",{"code":4,"msg":82,"data":132},{"doc_id":79,"user_id":133,"nickname":42,"user_avatar":134,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":140,"language":141,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":142,"faqs":143,"seo_title":144,"seo_description":12,"update_tm":145,"read_time":146,"preview_page_count":33,"preview_urls":147},4810365810221,"https://ap-avatar.wpscdn.com/davatar_155a257f0dc6eb9ab79c44ca47cae57d","Article  \nPrognostic Value of HHLA2 in Patients with Solid Tumors: A Meta-Analysis  \nAgnieszka Kula 1,*, Miriam Dawidowicz 1, Sylwia Mielcarska 2, Elbieta ´Swi˛etochowska 2  \nand Dariusz Waniczek 1, *  \n1 Department of Oncological Surgery, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-808 Katowice, Poland; [d201069@365.sum.edu.pl](d201069@365.sum.edu.pl)  \n2 Department of Medical and Molecular Biology, Faculty of Medical Sciences in Zabrze, Medical University of Silesia, 41-800 Zabrze, Poland; [d201109@365.sum.edu.pl](d201109@365.sum.edu.pl) (S.M.); [eswietochowska@365.sum.edu.pl](eswietochowska@365.sum.edu.pl) (E.´S .)  \n* Correspondence: [d201070@365.sum.edu.pl](d201070@365.sum.edu.pl) (A.K.); [dwaniczek@365.sum.edu.pl](dwaniczek@365.sum.edu.pl) (D.W.)  \nAbstract: HHLA2 is a checkpoint from the B7 family that can play a co-stimulatory or co-inhibitory role in cancer, depending on the binding receptor. The aim of this meta-analysis was to assess the relationship between HHLA2 levels and its impact on the prognosis of patients with solid cancers. The study used data from PubMed, Embase, Web of Science (WOS), Cochrane and SCOPUS databases. The R studio software was used for the data analysis. The study assessed overall survival (OS), disease-specific survival (DSS), progression-free survival (PFS), recurrence-free survival (RFS), and disease-free survival (DFS) by pooling appropriate hazard ratios (HR) . Eighteen studies (2880 patients’data) were included. High expression of HHLA2 was associated with worse OS (HR = 1.58, 95% CI: 1.23–2.03), shorter RFS (HR = 1.95, 95% CI: 1.38–2.77) and worse DFS (HR = 1.45, 95% CI: 1.01–2.09) inpatients with solid cancers. The current study suggests that high expression of HHLA2 is associated with poorer prognosis in patients with solid cancers.  \nCitation: Kula, A.; Dawidowicz, M.; Mielcarska, S.; ´Swi˛etochowska, E.; Waniczek, D. Prognostic Value of HHLA2 in Patients with Solid Tumors:  \nA Meta-Analysis. Int. J. Mol. Sci. 2024, 25, 4760. [https://doi.org/10.3390/](https://doi.org/10.3390/)[ ](https://doi.org/10.3390/)ijms25094760  \nAcademic Editors: Stergios Boussiosand Matin Sheriff  \nReceived: 25 March 2024  \nRevised: 22 April 2024  \nAccepted: 24 April 2024  \nPublished: 26 April 2024  \nCopyright: © 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ([https://](https://)[ ](https://)[creativecommons.org/licenses/by/](creativecommons.org/licenses/by/)[ ](creativecommons.org/licenses/by/)[4.0/](4.0/)) .  \nKeywords: HHLA2; solid cancers; meta-analysis; overall survival (OS); progression-free survival (PFS); recurrence-free survival (RFS); disease-free survival (DFS)  \n1. Introduction  \nImmune checkpoint blockade (ICB) therapies treat cancers by releasing the inhibiting signal and stimulating the host’s immune system. Immunotherapy blocking the PDL1/PD1 pathway has been a successful clinical advancement in the treatment of various cancers such as non-small cell lung cancer, melanoma, renal cell carcinoma, etc. [1] . Unfortunately, many tumors are resistant to current immunotherapy, and not every patient benefits from this innovative treatment [2] . Recently, much attention has been paid to studying immune pathways to find new targets for therapy. The search for new targets is intended to improve current immunotherapy and increase the number of treated patients. The human endogenous retrovirus-H Long repeat-associating 2 (HHLA2) is a member of the B7 family, and its gene was identified and first described in 1999 [3] . HHLA2 is an atypical B7 family checkpoint that differs from other members’ structures and lacks orthologs in mice or rats. This molecule is constitutively expressed in antigen-presenting cells (APC) in humans, in normal tissues, and is increased in various cancers such as breast, lung, thyroid, ovary, pancreas, liver,","cbCais2rHV1OrTs4","https://ap.wps.com/l/cbCais2rHV1OrTs4","pdf",4010912,15,"English","# Introduction\n## Immune checkpoint blockade and rationale for studying HHLA2\n# Prognostic value and study approach\n## Meta-analysis design and outcomes assessed","[{\"question\":\"What is HHLA2 and why is it relevant to cancer prognosis?\",\"answer\":\"HHLA2 is an immune checkpoint from the B7 family that can act as co-stimulatory or co-inhibitory depending on its receptor interactions. Because it influences anti-tumor immune activity, it may impact patient outcomes.\"},{\"question\":\"How was the meta-analysis conducted and which databases were used?\",\"answer\":\"The study pooled data from PubMed, Embase, Web of Science, Cochrane, and Scopus. R studio software was used for statistical analysis with hazard ratio pooling across survival endpoints.\"},{\"question\":\"What outcomes were associated with high HHLA2 expression in solid tumors?\",\"answer\":\"High HHLA2 expression was linked to worse overall survival (OS), shorter recurrence-free survival (RFS), and worse disease-free survival (DFS) across the included studies.\"}]","Prognostic Value of HHLA2 in Patients with Solid Tumors - A Meta-Analysis | PDF",1790014247,38,[148,152,156,160],{"page_no":22,"url":149,"width":150,"height":151},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f45c2402dbddf9877b988d32d827f3e7.webp",983,1390,{"page_no":26,"url":153,"width":154,"height":155},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/51e7e3ee0e9d3e48e43a4f99e63750e4.webp",982,1388,{"page_no":30,"url":157,"width":158,"height":159},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c78975958fe4e0620f4acf0d1abe11e0.webp",981,1387,{"page_no":33,"url":161,"width":162,"height":163},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0bb1c670216a38556f80d9640de12001.webp",980,1385]